At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 93 enrolled
Drug / intervention
AZD8848 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Investigate the Efficacy, Tolerability, and Safety of Different Dosing Regimens of AZD8848 Administered Intranasally to Seasonal Allergic Rhinitis Patients Out of Pollen Season in a Nasal Allergen Challenge Model
In Brief
A Phase 2 clinical trial evaluating AZD8848, Placebo, and 1 other intervention for Allergic Rhinitis. Completed, enrolled 93 participants across 2 sites.
Detailed Summary
The primary purpose of this study is to investigate effect, tolerability and safety of different dosing regimens of AZD8848 administered intranasally to seasonal allergic rhinitis patients out of season in an allergen challenge model.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesSweden
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartSep 2010
Primary CompletionDec 2010
Study CompletionJan 2012
TodayJul 2026
First PostedAug 19, 2010
Enrollment StartSep 1, 2010
Primary CompletionDec 1, 2010
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.9 years ago
Interventions
AZD8848drug
Nasal spray solution, intranasal, three times weekly for one month
Placebodrug
Nasal spray solution, intranasal, three times weekly for one month
AZD8848 and placebodrug
Nasal spray solution, intranasal, three times weekly for one month